Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV002261579 | SCV002541439 | uncertain significance | not provided | 2021-12-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003095878 | SCV003253457 | uncertain significance | Glycogen storage disease, type II | 2022-06-24 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with arginine, which is basic and polar, at codon 265 of the GAA protein (p.Ser265Arg). This variant is present in population databases (rs779785396, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with GAA-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GAA protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV002261579 | SCV003834053 | uncertain significance | not provided | 2020-02-12 | criteria provided, single submitter | clinical testing | |
Molecular Genetics, |
RCV003095878 | SCV004812705 | uncertain significance | Glycogen storage disease, type II | 2023-03-30 | criteria provided, single submitter | clinical testing | This sequence change in GAA is predicted to replace serine with arginine at codon 265, p.(Ser265Arg). The serine residue is weakly conserved (100 vertebrates, UCSC), and is not located in an annotated functional domain. There is a large physicochemical difference between serine and arginine. The highest population minor allele frequency in gnomAD v2.1 is 0.003% (3/113,280 alleles) in the European (non-Finnish) population, which is consistent with recessive disease. To our knowledge, this variant has not been reported in the literature in any individuals with GAA-related disease. Multiple lines of computational evidence have conflicting predictions for the missense substitution (4/6 algorithms predict benign). Based on the classification scheme RMH Modified ACMG Guidelines v1.5.1, this variant is classified as a VARIANT OF UNCERTAIN SIGNIFICANCE. Following criteria are met: PM2_Supporting. |